Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient’s immune system to attack cancer. In 1891, William B. Coley, MD, first attempted to harness the immune system for treating cancer. The scientific community has been pursuing research for the development of CAR T-cell therapy over a century. The engineered CAR T-cell receptors were first created and developed in 1987 by Dr. Zelig Eshhar, an Israeli immunologist from the Weizmann Institute of Science, Israel. On August 30, 2017, Kymriah (Tisagenlecleucel), a synthetic bio immune product of anti-CD19 chimeric antigen receptor (CAR) T-cells, was approved by the U.S. FDA for the treatment of cancers such as relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Novarts AG is the first company to get approval for the first CAR T-cell immunotherapy. Currently, CAR T-cell therapy is developed by more than 100 companies across the globe.

1. Technology Definition 

2. Research Scope 

3. Research Methodology 

4. Market Overview 

5. Global CAR T-Cell Therapy Market, $Million, 2019-2030

6. CAR T-Cell Therapy Patent Landscape 

7. Epidemiology of CAR T-Cell Therapy 

8. Industry Insights

9. CAR T-Cell Therapy Development and Manufacturing 

10. Market Dynamics

11. Global CAR T-Cell Therapy Market (by Application) 

12. Global CAR T-Cell Therapy Market (by Target Antigen) 

13. Global CAR T-Cell Therapy Market (by Region) 

14. Competitive Landscape

15. Company Profiles